Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 72 of 116

  1. Sorafenib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  2. Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin

    Bayer HealthCare AG

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

  3. Steroids switch

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  4. Stivarga 40 mg film-coated tablets

    Ningbo Cancer Hospital

    Bone sarcoma

    phase 2 small molecule active

    1 trial

  5. Streptococcus salivarius K12

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  6. Sunvozertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Surufatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  9. Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine

    Sun Yat-sen University

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  10. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  11. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  12. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  13. T2214

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  15. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  16. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  17. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  18. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  19. TAK-280-1501

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  20. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  21. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  22. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  23. TAK-676-1002

    Takeda

    Solid Neoplasm

    phase 2 small molecule active

    1 trial

  24. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  25. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  26. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  27. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  28. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  29. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  30. TAK-981

    Takeda

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  31. TAK-981

    Takeda

    Lymphoma, Non-Hodgkin

    phase 2 small molecule terminated

    1 trial

  32. TAK228

    Takeda

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  33. TARA-002

    Protara Therapeutics

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    3 trials

  34. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  35. TAS-120-203

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  36. TAS-120-206

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial

  37. TAX625

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  38. TCD17620

    Sanofi-aventis Healthcare Pty Ltd

    Solid tumor

    phase 2 small molecule active

    1 trial

  39. TCTLR-101

    Lacuna Pharma Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  40. TD001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  41. TEBENTAFUSP

    Fondazione Telethon ETS

    metastatic uveal melanoma HLA A*02:01 positive

    phase 2 small molecule active

    1 trial

  42. TED14856

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  43. TEDOPI for NSCLC non-small cell lung cancer

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  44. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  45. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial

  46. TEMOZOLOMIDE for locally advanced rectal cancer (LARC)

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 small molecule active

    1 trial

  47. TEP-64Cu-ATSM-Rectum

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  48. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.